منابع مشابه
Targeting Autophagy in BRAF-Mutant Tumors.
Recent studies have highlighted the opportunity to treat cancer by inhibiting autophagy, but have also raised important caveats with this idea. An article in this issue of Cancer Discovery adds to accumulating evidence suggesting that we should focus our efforts (at least initially) on specific tumors where we are most likely to see beneficial effects.
متن کاملEstablishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing
Pilocytic astrocytoma (PA) is the most frequent pediatric brain tumor. Activation of the MAPK pathway is well established as the oncogenic driver of the disease. It is most frequently caused by KIAA1549:BRAF fusions, and leads to oncogene induced senescence (OIS). OIS is thought to be a major reason for growth arrest of PA cells in vitro and in vivo, preventing establishment of PA cultures. Hen...
متن کاملTargeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers.
UNLABELLED Metabolomic analyses of human tumors and mouse models of cancer have identified key roles for autophagy in supporting mitochondrial metabolism and homeostasis. In this review, we highlight data suggesting that autophagy inhibition may be particularly effective in BRAF-driven malignancies. Catalytic BRAF inhibitors have profound efficacy in tumors carrying activating mutations in Braf...
متن کاملTitle: Molecular Pathways: Response and resistance to BRAF and MEK inhibitors in BRAF tumors Running title: Molecular Pathways: Targeting BRAF tumors
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract The RAS-RAF-MEK-ERK pathway plays a central role in driving proliferation, survival and metastasis signals in tumor cells and the prevalence of oncogenic mutations in RAS and BRAF and upstream nodes makes this pathway the focus of significant oncology drug development efforts. This foc...
متن کاملCombined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
BACKGROUND Oncogenic RAS is a highly validated cancer target. Attempts at targeting RAS directly have so far not succeeded in the clinic. Understanding downstream RAS-effectors that mediate oncogenesis in a RAS mutant setting will help tailor treatments that use RAS-effector inhibitors either alone or in combination to target RAS-driven tumors. METHODOLOGY/PRINCIPAL FINDINGS In this study, we...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2019
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/noz036.249